AD/PD 2021 | Progress in Alzheimer’s disease: aducanumab, imaging, and blood biomarkers

Stephen Salloway, MD, MS, Butler Hospital and Brown University, Providence, RI, shares the latest advances in the field of Alzheimer’s disease (AD) and outlines exciting breakthroughs to expect in the coming years. Dr Salloway discusses advances in brain imaging that have allowed safe visualization of early pathological changes in AD, as well as plasma biomarkers under development that will improve early diagnosis and screening for treatments. Dr Salloway also talks about the progress underway in treating AD, with aducanumab representing a potential first-in-class disease targeting therapy. These developments are moving us into the modern era of AD prevention, early diagnosis, and efficacious treatment. This interview took place during the AD/PD™ 2021 conference.